Results 11 to 20 of about 10,632 (179)

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis

HIV Research & Clinical Practice, 2021
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety ...
Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy   +7 more
doaj   +1 more source

Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States

AIDS Research and Therapy, 2021
Introduction Although individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations.
Kunchok Dorjee, Manisha Desai, Tsering Choden, Sanjiv M. Baxi, Alan E. Hubbard, Arthur L. Reingold   +5 more
doaj   +1 more source

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances

Разработка и регистрация лекарственных средств, 2021
Introduction. Usage of aggressive conditions (solvents, high temperature, etc.) in a dosage form manufacturing can lead to a change in the properties of a pharmaceutical substance.
S. A. Zolotov, I. A. Dain, N. B. Demina, A. S. Zolotova, E. S. Ponomarev   +4 more
doaj   +1 more source

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro [PDF]

Antimicrobial Agents and Chemotherapy, 2017
ABSTRACT Treatment of HIV-infected patients coinfected with Mycobacterium tuberculosis is challenging due to drug-drug interactions (DDIs) between antiretrovirals (ARVs) and antituberculosis (anti-TB) drugs.
Roberts, Owain, Khoo, Saye, Owen, Andrew, Siccardi, Marco   +3 more
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

AIDS Research and Treatment, 2012
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus   +7 more
doaj   +1 more source

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

Future Journal of Pharmaceutical Sciences, 2022
Background The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography. Result The separation
Challamalla Pavani, E. Susithra
doaj   +1 more source

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study

Current Issues in Molecular Biology, 2022
Candida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has ...
Juliana de C. Fenley, Patrícia P. de Barros, Paulo H. F. do Carmo, Maíra T. Garcia, Rodnei D. Rossoni, Juliana C. Junqueira   +5 more
doaj   +1 more source

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Frontiers in Medicine, 2021
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID ...
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Marialaura Bonaccio, Raffaele Bruno, Raffaele Bruno, Roberto Cauda, Roberto Cauda, Alessandro Gialluisi, Giovanni Guaraldi, Lorenzo Menicanti, Marco Mennuni, Ilaria My, Agostino Parruti, Giuseppe Patti, Stefano Perlini, Stefano Perlini, Francesca Santilli, Carlo Signorelli, Giulio G. Stefanini, Alessandra Vergori, Walter Ageno, Luca Aiello, Piergiuseppe Agostoni, Piergiuseppe Agostoni, Samir Al Moghazi, Rosa Arboretti, Filippo Aucella, Greta Barbieri, Martina Barchitta, Alessandro Bartoloni, Carolina Bologna, Paolo Bonfanti, Paolo Bonfanti, Lucia Caiano, Laura Carrozzi, Antonio Cascio, Giacomo Castiglione, Mauro Chiarito, Arturo Ciccullo, Antonella Cingolani, Antonella Cingolani, Francesco Cipollone, Claudia Colomba, Crizia Colombo, Francesco Crosta, Giovanni Dalena, Chiara Dal Pra, Gian Battista Danzi, Damiano D'Ardes, Katleen de Gaetano Donati, Francesco Di Gennaro, Giuseppe Di Tano, Gianpiero D'Offizi, Tommaso Filippini, Francesco Maria Fusco, Carlo Gaudiosi, Ivan Gentile, Giancarlo Gini, Elvira Grandone, Gabriella Guarnieri, Gennaro L. F. Lamanna, Giovanni Larizza, Armando Leone, Veronica Lio, Angela Raffaella Losito, Gloria Maccagni, Stefano Maitan, Sandro Mancarella, Rosa Manuele, Massimo Mapelli, Massimo Mapelli, Riccardo Maragna, Riccardo Maragna, Lorenzo Marra, Giulio Maresca, Claudia Marotta, Franco Mastroianni, Maria Mazzitelli, Alessandro Mengozzi, Francesco Menichetti, Jovana Milic, Filippo Minutolo, Beatrice Molena, R. Mussinelli, Cristina Mussini, Maria Musso, Anna Odone, Marco Olivieri, Emanuela Pasi, Annalisa Perroni, Francesco Petri, Biagio Pinchera, Carlo A. Pivato, Venerino Poletti, Claudia Ravaglia, Marco Rossato, Marianna Rossi, Anna Sabena, Francesco Salinaro, Vincenzo Sangiovanni, Carlo Sanrocco, Laura Scorzolini, Raffaella Sgariglia, Paola Giustina Simeone, Michele Spinicci, Enrico Maria Trecarichi, Giovanni Veronesi, Roberto Vettor, Andrea Vianello, Marco Vinceti, Marco Vinceti, Elena Visconti, Laura Vocciante, Raffaele De Caterina, Licia Iacoviello, Licia Iacoviello, The COVID-19 RISK and Treatments (CORIST) Collaboration   +119 more
doaj   +1 more source

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

BMC Infectious Diseases, 2017
Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration   +14 more
doaj   +1 more source

Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

HIV Research & Clinical Practice, 2022
Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral ...
Malte Monin, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D. Spinner, Christoph Boesecke, on behalf of the DUALIS STUDY GROUP   +18 more
doaj   +1 more source